Ketamine supplier gets 15 years in Perry-linked case

Jasveen Sangha was sentenced on Wednesday, April 8, 2026, to 15 years in federal prison in Los Angeles, California, after admitting to ketamine distribution tied to the death of actor Matthew Perry. The case centers on ketamine sales that prosecutors linked to Perry’s death in October 2023. Officials said Sangha’s sentence followed a guilty plea entered in September to charges that included distribution of ketamine resulting in death or serious bodily injury.

Sangha, 42, was described as operating a drug trafficking business from her residence in North Hollywood. In court filings tied to her plea, she acknowledged selling approximately 50 vials of ketamine to Perry for $11,000. The plea agreement stated that the sales included the batch connected to Perry’s death.

U.S. District Judge Sherilyn Peace Garnett said Sangha was among the most culpable of the five people charged in connection with Perry’s death. Alongside the prison term, the court imposed three years of supervised release. Sangha’s defense asked for a sentence of time served, arguing she had no prior criminal history.

The plea agreement also addressed an earlier sale involving a different individual. It stated that Sangha sold four ketamine vials to Cody McLaury in August 2019, and that McLaury later died from an overdose in which ketamine was a contributing factor. The sentencing outcome in Los Angeles adds a major resolution for one defendant in the broader federal case involving five charged individuals.

Ketamine is used in medical settings, but the charges in this case focused on unlawful distribution and the consequences described in the plea. The court’s findings and the judge’s assessment of culpability underscore how federal authorities can pursue severe penalties when a controlled substance distribution is tied to death or serious bodily injury, based on the admissions and evidence presented in court.

Some aspects of the wider case remain outside the scope of this sentencing, including how the proceedings will conclude for the other charged individuals. The court record in this matter establishes Sangha’s admissions regarding the quantities sold, the price paid, and the two deaths in which ketamine was cited as linked or contributing, but it does not detail in this account the full timeline of the broader investigation.